{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:23:52Z","timestamp":1792657432867,"version":"4.5.0"},"reference-count":394,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000209","name":"National Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinejcf.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cardfail.2024.08.045","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T11:30:18Z","timestamp":1728991818000},"page":"415-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-8070","authenticated-orcid":false,"given":"MICHELLE WEISFELNER","family":"BLOOM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JACQUELINE B.","family":"VO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JO E.","family":"RODGERS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALANA M.","family":"FERRARI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANJU","family":"NOHRIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANITA","family":"DESWAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RICHARD K.","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHELLE M.","family":"KITTLESON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JENICA N.","family":"UPSHAW","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICOLAS","family":"PALASKAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNE","family":"BLAES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHERRY-ANN","family":"BROWN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BONNIE","family":"KY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"LENIHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATHEW S.","family":"MAURER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANECITA","family":"FADOL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KERRY","family":"SKURKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTINE","family":"CAMBARERI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CYNTHIA","family":"CHAUHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANA","family":"BARAC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2024.08.045_bib0001","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.jacc.2020.03.067","article-title":"Mechanistic biomarkers informative of both cancer and cardiovascular disease: JACC State-of-the-Art Review","volume":"75","author":"Narayan","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0002","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2021.11.008","article-title":"Cardiovascular disease among patients with AML and CHIP-related mutations","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2019.01.082","article-title":"Arterial hypertension in cancer: The elephant in the room","volume":"281","author":"Tini","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0006","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","article-title":"The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0007","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/HYPERTENSIONAHA.111.189258","article-title":"Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project","volume":"59","author":"Stocks","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0008","doi-asserted-by":"crossref","first-page":"g7607","DOI":"10.1136\/bmj.g7607","article-title":"Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies","volume":"350","author":"Tsilidis","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0009","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/cvr\/cvz035","article-title":"Common risk factors for heart failure and cancer","volume":"115","author":"Meijers","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaccao.2022.01.095","article-title":"Association of cardiometabolic disease with cancer in the community","volume":"4","author":"Liu","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0011","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking heart failure to cancer: background evidence and research perspectives","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaccao.2022.01.100","article-title":"Incident cardiovascular disease among adults with cancer: a population-based cohort study","volume":"4","author":"Paterson","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaccao.2022.01.099","article-title":"Lifestyle and cardiovascular risk factors associated with heart failure subtypes in postmenopausal breast cancer survivors","volume":"4","author":"Reding","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0014","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaccao.2020.09.005","article-title":"Temporal associations and outcomes of breast cancer and heart failure in postmenopausal women","volume":"2","author":"Lam","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0015","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0016","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. a scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0017","article-title":"Risk of cancer after diagnosis of cardiovascular disease","author":"Bell","year":"2023","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0018","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2013.04.088","article-title":"Patients with heart failure have an increased risk of incident cancer","volume":"62","author":"Hasin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0019","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaccao.2021.11.007","article-title":"Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort","volume":"4","author":"Bertero","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0020","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2016.04.053","article-title":"Heart failure after myocardial infarction is associated with increased risk of cancer","volume":"68","author":"Hasin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0021","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0022","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0023","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016309","article-title":"Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis","volume":"9","author":"Tini","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0025","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0026","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology State-of-the-Art Review","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0027","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0028","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0030","unstructured":"Federal Drug Administration. HERCEPTIN (trastuzumab)."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0031","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0032","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0033","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Pond\u00e9","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0035","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0036","first-page":"1","article-title":"Cyclophosphamide-induced cardiotoxicity","volume":"2","author":"Kamel","year":"2022","journal-title":"Int J Pharm Med Sci"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0037","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00520-023-07951-9","article-title":"Clinical features and outcomes of patients admitted to the ICU for cyclophosphamide-associated cardiac toxicity: a retrospective cohort","volume":"31","author":"Vennier","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0038","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0039","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cam4.3903","article-title":"Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer","volume":"10","author":"Jones","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0040","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1200\/JCO.2011.38.5278","article-title":"Takotsubo cardiomyopathy and Fluorouracil: case report and review of the literature","volume":"30","author":"Grunwald","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0043","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0044","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaccao.2022.07.009","article-title":"Cellular and molecular mechanisms of MEK1 inhibitor-induced cardiotoxicity","volume":"4","author":"Beck","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0047","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0048","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy-related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0049","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0050","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0051","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0052","first-page":"14","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"Mohammed","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0053","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/DDDT.S159818","article-title":"Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib","volume":"12","author":"Zhao","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0054","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0056","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0057","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0058","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0059","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0060","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0061","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0062","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0063","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0064","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0066","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0067","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0068","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0069","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0071","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0072","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology Primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0073","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","article-title":"Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel","volume":"74","author":"Desai","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0074","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fonc.2015.00039","article-title":"Radiation-induced heart disease: pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"JAHA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0076","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacbts.2018.01.014","article-title":"Radiation-induced endothelial vascular injury: a review of possible mechanisms","volume":"3","author":"Venkatesulu","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0077","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ccd.27660","volume":"92","author":"Hirshfeld","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0078","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0079","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ahj.2004.12.026","article-title":"Diastolic dysfunction after mediastinal irradiation","volume":"150","author":"Heidenreich","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0081","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0082","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0083","unstructured":"U.S Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE), Version 5.0. Nov.27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.html."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0084","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cardfail.2024.08.045_bib0085","first-page":"352","volume":"23","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0086","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0087","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaccao.2020.02.016","article-title":"Longitudinal changes in echocardiographic parameters of cardiac function in pediatric cancer survivors","volume":"2","author":"Border","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0088","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0089","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0090","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J Clini Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0091","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ehjci\/jeaa288","article-title":"Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction","volume":"22","author":"Demissei","year":"2021","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0092","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijcard.2019.03.013","article-title":"Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - a real-world data-based, nationwide classification analysis","volume":"285","author":"Fogarassy","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0093","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0569","article-title":"Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: a systematic review","volume":"6","author":"Kabore","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2019.04.012","article-title":"Personalized decision making in early stage breast cancer: applying clinical prediction models for anthracycline cardiotoxicity and breast cancer mortality demonstrates substantial heterogeneity of benefit-harm trade-off","volume":"19","author":"Upshaw","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0095","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1470-2045(23)00012-8","article-title":"Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"24","author":"Ehrhardt","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0096","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Survivorship. Published online, 2023."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0097","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0098","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0099","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in multimodality imaging in cardio-oncology: JACC State-of-the-Art Review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0101","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77:","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11897-022-00544-3","article-title":"LVEF by multigated acquisition scan compared to other imaging modalities in cardio-oncology: a systematic review","volume":"19","author":"Printezi","year":"2022","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0103","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0104","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0105","unstructured":"National Cancer Institute and Children's Oncology Group. Children's Oncology Group (COG). Homepage on the internet]; cited June 2023. Available at:https:\/\/childrensoncologygroup.org\/survivorshipguidelines."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/hematology.2022000342","article-title":"Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity","author":"Bottinor","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0107","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jcmg.2018.04.028","article-title":"Radiation-Associated cardiac disease: a practical approach to diagnosis and management","volume":"11","author":"Desai","year":"2018","journal-title":"JACC Cardiovasc Imag"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0108","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fcvm.2018.00083","article-title":"Radiation matters of the heart: a mini review","volume":"5","author":"Menezes","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0109","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fcvm.2018.00005","article-title":"Radiation-induced cardiovascular disease: mechanisms and importance of linear energy transfer","volume":"5","author":"Sylvester","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ijrobp.2016.12.017","article-title":"Utility of deep inspiration breath hold for left-sided breast radiation therapy in preventing early cardiac perfusion defects: a prospective study","volume":"97","author":"Zagar","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0111","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025556","article-title":"Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0112","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0113","unstructured":"DOXIL FDA Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12020437","article-title":"FDA and EMA approvals of new breast cancer drugs-a comparative regulatory analysis","volume":"12","author":"Leo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0115","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0116","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/CAD.0000000000000521","article-title":"Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600\u2009mg\/m2 in recurrent ovarian cancer","volume":"28","author":"Pendlebury","year":"2017","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0117","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000312644","article-title":"High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies","volume":"56","author":"Kesterson","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0118","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/annonc\/mdl484","article-title":"Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer","volume":"18","author":"Andreopoulou","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0119","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/cytarabine liposome: a review in acute myeloid leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0120","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0121","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1200\/JCO.2023.41.16_suppl.7029","article-title":"Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia","volume":"41","author":"Mitchell","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0122","unstructured":"Food and Drug Administration. Zinecard (dexrazoxane). Accessed May 23, 7AD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020212s017lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0124","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174421","article-title":"Anthracyclines strike back: rediscovering non-pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer","volume":"13","author":"Schettini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0125","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0126","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.33974","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group","volume":"128","author":"Chow","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0127","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.jacc.2019.04.006","article-title":"Lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all","volume":"73","author":"Barac","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0129","first-page":"33","article-title":"Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial","volume":"7","author":"Mecinaj","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0131","first-page":"318","article-title":"The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0132","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0133","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0134","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ehf2.12695","article-title":"Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial","volume":"7","author":"Meessen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0135","first-page":"46","article-title":"Hypertension in cardio-oncology clinic: an update on etiology, assessment, and management","volume":"9","author":"Askarinejad","year":"2023","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0136","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0137","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaccao.2019.08.012","article-title":"Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor","volume":"1","author":"Waliany","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0138","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0139","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0140","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0141","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1161\/CIRCULATIONAHA.119.040625","article-title":"The New 2019 AHA\/ACC Guideline on the Primary Prevention of Cardiovascular Disease","volume":"142","author":"Bittner","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0142","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0143","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and cardiovascular injury","volume":"50","author":"Jones","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0144","first-page":"87","article-title":"Left ventricular dysfunction in cancer treatment","volume":"6","author":"Kenigsberg","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0145","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0146","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","article-title":"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function","volume":"185","author":"Khoury","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase i trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0148","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0149","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMoa1209825","article-title":"Ischemic heart disease after breast cancer radiotherapy","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0150","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.bbmt.2016.02.017","article-title":"Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors","volume":"22","author":"Leger","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0151","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jacc.2019.03.500","article-title":"Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer","volume":"73","author":"Atkins","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0152","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0153","unstructured":"Docetaxel FDA Label. Published online August 2, 2023."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0154","unstructured":"Gemcitabine FDA Label. Published online August 2, 2023."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3349\/ymj.2010.51.2.151","article-title":"Interpretation and use of natriuretic peptides in non-congestive heart failure settings","volume":"51","author":"Tsai","year":"2010","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0156","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1161\/CIRCULATIONAHA.118.039180","article-title":"Representation of patients with cardiovascular disease in pivotal cancer clinical trials","volume":"139","author":"Bonsu","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0157","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allerg Immunol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0158","unstructured":"Daratumumab FDA label."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0159","first-page":"1","article-title":"Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series","volume":"5","author":"Ganatra","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0160","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1634\/theoncologist.2016-0412","article-title":"SAFE-HEaRt: rationale and design of a pilot study investigating cardiac safety of HER2 targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function","volume":"22","author":"Lynce","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0161","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaoncol.2015.1787","article-title":"Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices: clinical incidence and predictors","volume":"1","author":"Grant","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0162","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1002\/mp.13838","article-title":"Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: a report of the AAPM TG-203(dagger)","volume":"46","author":"Miften","year":"2019","journal-title":"Med Phys"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0163","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamacardio.2023.0303","article-title":"Association of preexisting heart failure with outcomes in older patients with diffuse large B-cell lymphoma","volume":"8","author":"Upshaw","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0164","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0165","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0166","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ejhf.2818","article-title":"Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials","volume":"25","author":"Dobbin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0167","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/cvr\/cvac132","article-title":"Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies","volume":"118","author":"de Wit","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0168","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00392-019-01430-0","article-title":"Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry","volume":"108","author":"Ergatoudes","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0169","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1002\/ehf2.13533","article-title":"Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the KaRen study","volume":"8","author":"Shahim","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0171","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-022-06586-4","article-title":"Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer","volume":"193","author":"Kwan","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0172","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcad.2022.10.005","article-title":"Determinants of oxygen utilization in breast cancer: similarities between heart failure with preserved ejection fraction","volume":"74","author":"Haykowsky","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0173","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1042\/CS20160479","article-title":"Pathophysiology of exercise intolerance in breast cancer survivors with preserved left ventricular ejection fraction","volume":"130","author":"Haykowsky","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0174","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaccao.2021.08.011","article-title":"Common pathophysiology in cancer, atrial fibrillation, atherosclerosis, and thrombosis: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Leiva","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002883","article-title":"Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women","volume":"9","author":"Eaton","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0176","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/heartjnl-2022-321859","article-title":"A narrative review of heart failure with preserved ejection fraction in breast cancer survivors","volume":"109","author":"Yogeswaran","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0177","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0178","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaccao.2021.12.002","article-title":"From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach","volume":"4","author":"Minotti","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0179","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.117.246140","article-title":"Low-dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites","volume":"364","author":"Salvatorelli","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015598","article-title":"Anticancer therapy-related increases in arterial stiffness: a systematic review and meta-analysis","volume":"9","author":"Parr","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0181","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0182","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ccep.2020.11.004","article-title":"Atrial fibrillation and heart failure: epidemiology, pathophysiology, prognosis, and management","volume":"13","author":"Ariyaratnam","year":"2021","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0183","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11897-023-00587-0","article-title":"Cardiotoxicity of anti-cancer radiation therapy: a focus on heart failure","volume":"20","author":"Ritter","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0184","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/bs.apha.2022.02.002","article-title":"Beyond hypertension: diastolic dysfunction associated with cancer treatment in the era of cardio-oncology","volume":"94","author":"Minotti","year":"2022","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0185","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0186","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0187","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-016-0440-y","article-title":"Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimus","volume":"11","author":"Pavel","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0188","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0189","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tcm.2018.06.001","article-title":"Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities","volume":"29","author":"Guha","year":"2019","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0191","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2174\/1570161117666190130165810","article-title":"Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment","volume":"17","author":"Budolfsen","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0192","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0193","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1291\/hypres.31.679","article-title":"Exaggerated hypertensive response to exercise in patients with diastolic heart failure","volume":"31","author":"Kato","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0194","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0195","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2012.05.014","article-title":"Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction","volume":"110","author":"Anjan","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0196","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCULATIONAHA.116.024822","article-title":"Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study","volume":"135","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0197","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaccao.2020.08.014","article-title":"Cardiac biomarkers during cancer therapy: practical applications for cardio-oncology","volume":"2","author":"Alvarez-Cardona","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0198","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178607","article-title":"Plasma brain natriuretic peptide levels are elevated in patients with cancer","volume":"12","author":"Bando","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0199","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCHEARTFAILURE.114.001615","article-title":"Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials","volume":"8","author":"Pandey","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0201","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0202","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0204","unstructured":"FDA Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Published 2022. Accessed August 10, 2023. fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0205","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0206","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010881","article-title":"Clinical features and outcomes of patients with malignancy and Takotsubo syndrome: observations From the International Takotsubo Registry","volume":"8","author":"Cammann","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0207","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/cncr.34095","article-title":"Solidifying roles, responsibilities, and the process of navigation across the continuum of cancer care: the Professional Oncology Navigation Task Force","volume":"128","author":"Franklin","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0208","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","article-title":"Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support)","volume":"63","author":"Oliveira","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0209","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/ehf2.13362","article-title":"Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation","volume":"8","author":"Guha","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0210","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009772","article-title":"Characteristics and outcome of patients with a history of cancer undergoing durable left ventricular assist device implantation","volume":"16","author":"Tie","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0211","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaccao.2021.04.008","article-title":"Left ventricular assist devices in patients with active malignancies","volume":"3","author":"Schlam","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0212","doi-asserted-by":"crossref","first-page":"301","DOI":"10.21037\/acs-2020-cfmcs-10","article-title":"Development of malignancies and their outcomes in patients supported on continuous-flow left ventricular assist devices-a systematic review","volume":"10","author":"Maynes","year":"2021","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0213","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.healun.2012.09.013","article-title":"The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary","volume":"32","author":"Feldman","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0214","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.healun.2019.08.004","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match","volume":"38","author":"Khush","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jacc.2017.10.077","article-title":"Temporal trends of de novo malignancy development after heart transplantation","volume":"71","author":"Youn","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0216","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13593","volume":"16","author":"Zwald","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0217","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/archdermatol.2009.276","article-title":"Incidence of and risk factors for skin cancer after heart transplant","volume":"145","author":"Brewer","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0218","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10741-018-9691-2","article-title":"Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis","volume":"23","author":"Briasoulis","year":"2018","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0219","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.trim.2015.04.003","article-title":"Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update","volume":"32","author":"Hertig","year":"2015","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0220","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.jacc.2019.03.499","article-title":"Incidence of malignancies in patients treated with sirolimus following heart transplantation","volume":"73","author":"Asleh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0221","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fonc.2019.00160","article-title":"Dissecting the multiplicity of immune effects of immunosuppressive drugs to better predict the risk of de novo malignancies in solid organ transplant patients","volume":"9","author":"Cangemi","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0222","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008968","article-title":"Impact of pretransplant malignancy on heart transplantation outcomes: contemporary United Network for Organ Sharing analysis amidst evolving cancer therapies","volume":"15","author":"Batra","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0223","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.amjcard.2012.10.048","article-title":"Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy","volume":"111","author":"Lenneman","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0224","first-page":"294","article-title":"Heart transplantation in adriamycin-associated cardiomyopathy in the contemporary era of advanced heart failure therapies","volume":"3","author":"Ramu","year":"2021","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3322\/caac.21446","article-title":"Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"68","author":"Smith","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0226","unstructured":"United States Preventive Task Force. Published Recommendations. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0227","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/tri.13520","article-title":"Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines","volume":"32","author":"Crow","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0228","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0229","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0230","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.22.00369","article-title":"Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program","volume":"40","author":"Naqash","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0231","doi-asserted-by":"crossref","first-page":"e16373","DOI":"10.1016\/j.heliyon.2023.e16373","article-title":"Cardiovascular events after the initiation of immune checkpoint inhibitors","volume":"9","author":"Suzuki","year":"2023","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.cardfail.2024.08.045_bib0232","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0233","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0234","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0235","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0236","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin i during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0237","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1634\/theoncologist.2019-0040","article-title":"Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the Memorial Sloan Kettering Cancer Center experience","volume":"24","author":"Lee Chuy","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.cardfail.2024.08.045_bib0238","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0239","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0240","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0241","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0046-8177(87)80363-5","article-title":"Myocarditis: the Dallas criteria","volume":"18","author":"Aretz","year":"1987","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0242","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0243","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ejhf.2190","article-title":"Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society position pstatement on endomyocardial biopsy","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0244","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejca.2022.07.018","article-title":"Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry","volume":"177","author":"Nowatzke","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0246","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11883-017-0658-x","article-title":"Radiation-Induced Cardiovascular Disease","volume":"19","author":"Raghunathan","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0247","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11936-013-0259-0","article-title":"Radiation-induced cardiovascular disease","volume":"15","author":"Mousavi","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0248","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0046-8177(96)90447-5","article-title":"Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases","volume":"27","author":"Veinot","year":"1996","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0249","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1590\/1806-9282.62.02.192","article-title":"Martins Wde A. Cardiovascular effects of radiotherapy on the patient with cancer","volume":"62","author":"Moreira","year":"2016","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0250","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/01.CIR.100.13.1380","article-title":"Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy","volume":"100","author":"Ling","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0251","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3857\/roj.2021.00766","article-title":"An overview of radiation-induced heart disease","volume":"40","author":"Ellahham","year":"2022","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0252","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0253","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/2012.jama.10759","article-title":"Prone vs supine positioning for breast cancer radiotherapy","volume":"308","author":"Formenti","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0254","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0360-3016(00)00512-5","article-title":"Reduction of cardiac volume in left-breast treatment fields by respiratory maneuvers: a CT study","volume":"47","author":"Lu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0255","first-page":"343","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC: CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0256","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-022-06515-5","article-title":"Trends in heart disease mortality among breast cancer survivors in the US, 1975\u20132017","author":"Vo","year":"2022","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0257","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0258","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.113.001435","article-title":"Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study","volume":"127","author":"Wu","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0259","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtcvs.2017.07.033","article-title":"The risk of reoperative cardiac surgery in radiation-induced valvular disease","volume":"154","author":"Ejiofor","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2017.02.014","article-title":"Percutaneous revascularization in patients treated with thoracic radiation for cancer","volume":"187","author":"Fender","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0261","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jaccao.2021.07.005","article-title":"Transcatheter compared with surgical aortic valve replacement in patients with previous chest-directed radiation therapy","volume":"3","author":"Yazdchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0262","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2016.03.014","article-title":"Heart transplantation outcomes in radiation-induced restrictive cardiomyopathy","volume":"22","author":"Al-Kindi","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0263","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0264","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11936-017-0543-5","article-title":"Pulmonary hypertension and cancer: etiology, diagnosis, and management","volume":"19","author":"Ballout","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0266","doi-asserted-by":"crossref","first-page":"299","DOI":"10.14744\/AnatolJCardiol.2023.3013","article-title":"Cancer therapy-related pulmonary hypertension: a review of mechanisms and implications for clinical practice","volume":"27","author":"G\u00fcrdo\u011fan","year":"2023","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0267","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0268","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0269","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09031936.00211811","article-title":"Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries","volume":"41","author":"Nagaraj","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0271","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0272","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy-associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0273","doi-asserted-by":"crossref","first-page":"4416- -26","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0274","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MBC.0000000000001043","article-title":"Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States","volume":"32","author":"Faiz","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0275","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv342","article-title":"Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review","volume":"108","author":"Wang","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0276","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0277","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186556","article-title":"Ponatinib and other CML tyrosine kinase inhibitors in thrombosis","volume":"21","author":"Zeng","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0278","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study","volume":"11","author":"Haguet","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0279","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0065-2018","article-title":"Tumoral pulmonary hypertension","volume":"28","author":"Price","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0280","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0281","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","article-title":"Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors","volume":"5","author":"Vasbinder","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0282","doi-asserted-by":"crossref","first-page":"460- -71","DOI":"10.1016\/j.jaccao.2020.06.011","article-title":"Left ventricular systolic function in long-term survivors of allogeneic hematopoietic stem cell transplantation","volume":"2","author":"Massey","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0283","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","article-title":"Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant","volume":"7","author":"P\u00e9rez-Valencia","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0284","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002007","article-title":"Early-onset cardiac dysfunction following allogeneic haematopoietic stem cell transplantation","volume":"9","author":"Moriyama","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0285","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18835","article-title":"Predicting short-term and long-term mortalities from sepsis in patients who receive allogeneic haematopoietic stem cell transplantation","author":"Wu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0286","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","article-title":"Late congestive heart failure after hematopoietic cell transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0287","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0288","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Saad","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0289","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2014.10.011","article-title":"Hematopoietic stem cell transplantation in patients with systolic dysfunction: can it be done?","volume":"21","author":"Hurley","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0290","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2009.06.001","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction","volume":"15","author":"Qazilbash","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0291","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-021-00850-3","article-title":"Cardiovascular issues in hematopoietic stem cell transplantation (HSCT)","volume":"22","author":"L\u00f3pez-Fern\u00e1ndez","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0292","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","article-title":"Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study","volume":"27","author":"Armstrong","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0293","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaccao.2020.04.007","article-title":"Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in pregnancy","volume":"2","author":"Nolan","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0294","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2018.07.085","article-title":"Cardiac outcomes in pregnant women with treated cancer","volume":"72","author":"Liu","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0295","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2016.11.040","article-title":"Cardiac Outcomes with pregnancy after cardiotoxic therapy for childhood cancer","volume":"69","author":"Thompson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0296","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2018.02.076","article-title":"Pregnancy outcomes in women with heart disease: the CARPREG II study","volume":"71","author":"Silversides","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0297","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0298","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008223","article-title":"Intersection of heart failure and pregnancy: beyond peripartum cardiomyopathy","volume":"14","author":"DeFilippis","year":"2021","journal-title":"Circulation Heart Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0299","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1161\/CIR.0000000000000772","article-title":"Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association","volume":"141","author":"Mehta","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0300","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1019284","article-title":"Trigger-related outcomes of takotsubo syndrome in a cancer population","volume":"9","author":"Safdar","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0301","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"5","author":"Desai","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0302","doi-asserted-by":"crossref","first-page":"74","DOI":"10.15420\/usc.2019.10.1","article-title":"Clinical features and outcomes of patients with chemotherapy-induced Takotsubo syndrome","volume":"13","author":"Storey","year":"2019","journal-title":"US Cardiol Rev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0303","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: endomyocardial biopsy provides pathological insights to dual diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0304","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ahj.2007.11.008","article-title":"Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): A mimic of acute myocardial infarction","volume":"155","author":"Prasad","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0305","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International expert consensus document on Takotsubo syndrome (part ii): diagnostic workup, outcome, and management","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0306","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10741-019-09773-6","article-title":"Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy","volume":"24","author":"Brunetti","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0307","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/clc.22280","article-title":"Lack of efficacy of drug therapy in preventing takotsubo cardiomyopathy recurrence: a meta-analysis","volume":"37","author":"Santoro","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0308","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijcard.2014.04.221","article-title":"Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy","volume":"174","author":"Singh","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0309","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/heartjnl-2021-320543","article-title":"Beta-blockers are associated with better long-term survival in patients with Takotsubo syndrome","volume":"108","author":"Silverio","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0310","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jnci\/djn310","article-title":"Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study","volume":"100","author":"Mertens","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0311","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacc.2022.04.042","article-title":"Cardiovascular disease risk among cancer survivors: the Atherosclerosis Risk In Communities (ARIC) study","volume":"80","author":"Florido","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0312","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.2022016487","article-title":"Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report","volume":"141","author":"Turcotte","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0313","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JOP.19.00801","article-title":"Survivorship care plans and the Commission on Cancer Standards: the increasing need for better strategies to improve the outcome for survivors of cancer","volume":"16","author":"Blaes","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0314","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium- and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0315","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0316","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djz108","article-title":"Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors","volume":"112","author":"Chen","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0317","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0318","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.jacc.2019.04.006","article-title":"lessons from primary cardiac prevention trials during trastuzumab therapy: end of one size fits all","volume":"73","author":"Barac","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0319","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/FJC.0000000000001342","article-title":"Hypertension in cancer survivors: a review of the literature and suggested approach to diagnosis and treatment","volume":"80","author":"Chuquin","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0320","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaccao.2019.11.009","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0321","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J Am Soc Echocardiog"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0322","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(19)31886-0","article-title":"Is it time to include cancer in cardiovascular risk prediction tools?","volume":"394","author":"Blaes","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0323","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024735","article-title":"Underdiagnosis and undertreatment of modifiable cardiovascular risk factors among survivors of childhood cancer","volume":"11","author":"Chow","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0324","unstructured":"Childhood Cancer Survivor Study. Cardiovascular Risk Calculator. https:\/\/ccss.stjude.org\/resources\/calculators\/cardiovascular-risk-calculator.html."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0325","unstructured":"Oncolink.org. https:\/\/www.oncolink.org\/"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0326","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0327","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11764-021-01018-6","article-title":"Outcomes of cancer survivorship education and training for primary care providers: a systematic review","volume":"16","author":"Chan","year":"2022","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0328","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s13187-019-01585-4","article-title":"Primary care providers\u2019 knowledge, attitudes, beliefs, and practices regarding their preparedness to provide cancer survivorship care","volume":"35","author":"Geramita","year":"2020","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0329","first-page":"32","article-title":"Palliative care referral criteria and outcomes in cancer and heart failure: a systematic review of literature","volume":"7","author":"Fadol","year":"2021","journal-title":"Cardiooncology"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0330","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1089\/jpm.2017.0392","article-title":"A review of the essential components of quality palliative care in the home","volume":"21","author":"Seow","year":"2018","journal-title":"J Palliat Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0331","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jpainsymman.2017.03.030","article-title":"World Health Organization Public Health Model: a roadmap for palliative care development","volume":"55","author":"Callaway","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0332","series-title":"Models and Strategies to Integrate Palliative Care Principles into Care for People with Serious Illness: Proceedings of a Workshop","article-title":"The National Academies Collection: Reports funded by National Institutes of Health","year":"2017"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0333","doi-asserted-by":"crossref","first-page":"780","DOI":"10.6004\/jnccn.2021.0033","article-title":"NCCN Guidelines\u00ae Insights: Palliative Care, Version 2.2021","volume":"19","author":"Dans","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0334","unstructured":"S.2243 - 118th Congress (2023-2024): Palliative Care and Hospice Education and Training Act, 2023. https:\/\/www.congress.gov\/bill\/118th-congress\/senate-bill\/2243"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0335","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jaccao.2019.10.003","article-title":"Cardio-oncology and the intersection of cancer and cardiotoxicity: the role of palliative care","volume":"1","author":"Cheng","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0336","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clon.2021.03.012","article-title":"What does a cardio-oncology service offer to the oncologist and the haematologist?","volume":"33","author":"Andres","year":"2021","journal-title":"Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0337","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0338","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1188\/22.CJON.E14-E25","article-title":"Oncology navigation standards of professional practice","volume":"26","year":"2022","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0339","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0340","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.1472","article-title":"Trends in cancer mortality among Black individuals in the US from 1999 to 2019","author":"Lawrence","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0341","first-page":"caac.21703","article-title":"American Cancer Society's report on the status of cancer disparities in the United States, 2021","author":"Islami","year":"2021","journal-title":"ACA Cancer J Clin"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0342","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023852","article-title":"Inequity in cardio-oncology: identifying disparities in cardiotoxicity and links to cardiac and cancer outcomes","volume":"10","author":"Ohman","year":"2021","journal-title":"JAHA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0343","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIR.0000000000001158","article-title":"Equity in cardio-oncology care and research: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0344","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1377\/hlthaff.2021.01394","article-title":"Systemic And Structural Racism: Definitions, Examples, Health Damages, And Approaches To Dismantling: Study examines definitions, examples, health damages, and dismantling systemic and structural racism","volume":"41","author":"Braveman","year":"2022","journal-title":"Health Affairs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/ace.2020.01.02","article-title":"A balancing act: racial disparities in cardiovascular disease mortality among women diagnosed with breast cancer","volume":"4","author":"Collin","year":"2020","journal-title":"Ann Cancer Epidemiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0346","first-page":"cncr.33889","article-title":"Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: impact of cardiovascular disease and clinical characteristics","author":"Connor","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0347","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz108","article-title":"Race differences in cardiovascular disease and breast cancer mortality among US women diagnosed with invasive breast cancer","volume":"48","author":"Troeschel","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0348","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaccao.2022.10.013","article-title":"Zarich S. Racial and ethnic disparities in all-cause and cardiovascular mortality among cancer patients in the U.S","volume":"5","author":"Zhu","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0349","doi-asserted-by":"crossref","first-page":"pkad024","DOI":"10.1093\/jncics\/pkad024","article-title":"Racial and ethnic disparities in treatment-related heart disease mortality among U.S. breast cancer survivors","author":"Vo","year":"2023","journal-title":"JNCI Cancer Spect"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0350","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40064-016-1726-3","article-title":"Risk of cancer-specific, cardiovascular, and all-cause mortality among Asian and Pacific Islander breast cancer survivors in the United States, 1991\u20132011","volume":"5","author":"Solanki","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0351","first-page":"djad069","article-title":"Cancer mortality rates by racial\/ethnic groups in the United States, 2018-2020","author":"Haque","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0352","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cardfail.2014.05.012","article-title":"Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population","volume":"20","author":"Baron","year":"2014","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0353","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.amjcard.2021.02.013","article-title":"Racial and socioeconomic disparities in cardiotoxicity among women with HER2-positive breast cancer","volume":"147","author":"Al-Sadawi","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0354","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027981","article-title":"Racial and ethnic differences in cardiac surveillance evaluation of patients treated with anthracycline-based chemotherapy","author":"DeRemer","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0355","doi-asserted-by":"crossref","first-page":"pkac083","DOI":"10.1093\/jncics\/pkac083","article-title":"County-level geographic disparities in cardiovascular disease mortality among US breast cancer survivors, 2000-2018","volume":"7","author":"Ho","year":"2023","journal-title":"JNCI Cancer Spect"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0356","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s11764-018-0678-8","article-title":"Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study","volume":"12","author":"Keegan","year":"2018","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0357","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1158\/1055-9965.EPI-18-1384","article-title":"Disparities in mortality from noncancer causes among adolescents and young adults with cancer","volume":"28","author":"Anderson","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0358","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaccao.2022.11.017","article-title":"Overcoming LGBTQI+ disparities in cardio-oncology: a call to action","volume":"5","author":"Sirufo","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0359","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/MLR.0000000000000417","article-title":"Racial\/ethnic disparities in time to a breast cancer diagnosis: the mediating effects of health care facility factors","volume":"53","author":"Molina","year":"2015","journal-title":"Med Care"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0360","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/jwh.2014.4773","article-title":"Diagnosis and surgical delays in African American and white women with early-stage breast cancer","volume":"24","author":"George","year":"2015","journal-title":"J Women's Health"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0361","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jamaoncol.2022.1990","article-title":"Multilevel factors associated with time to biopsy after abnormal screening mammography results by race and ethnicity","volume":"8","author":"Lawson","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0362","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2006.09.5539","article-title":"Lost opportunities: physicians\u2019 reasons and disparities in breast cancer treatment","volume":"25","author":"Bickell","year":"2007","journal-title":"JCO"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0363","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10549-018-4881-0","article-title":"Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database","volume":"172","author":"Parekh","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0364","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1377\/hlthaff.2011.1365","article-title":"Black Patients more likely than whites to undergo surgery at low-quality hospitals in segregated regions","volume":"32","author":"Dimick","year":"2013","journal-title":"Health Affairs"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0365","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2017.73.7932","article-title":"Factors that contributed to Black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013","volume":"36","author":"Jemal","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0366","first-page":"221","article-title":"A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change: closing the racial disparity gap in breast cancer","volume":"65","author":"Daly","year":"2015","journal-title":"CA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0367","first-page":"1","article-title":"The effects of navigation and types of neighborhoods on timely follow-up of abnormal mammogram among black women","volume":"3","author":"Kim","year":"2015","journal-title":"MRAJ"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0368","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jrh.12413","article-title":"evaluating travel distance to radiation facilities among rural and urban breast cancer patients in the Medicare population","volume":"36","author":"Longacre","year":"2020","journal-title":"J Rural Health"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0369","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106741","article-title":"Identifying key barriers to effective breast cancer control in rural settings","volume":"152","author":"Sprague","year":"2021","journal-title":"Prevent Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0370","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM199902253400806","article-title":"The effect of race and sex on physicians\u2019 recommendations for cardiac catheterization","volume":"340","author":"Schulman","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0371","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006872","article-title":"Implicit gender bias and the use of cardiovascular tests among cardiologists","volume":"6","author":"Daugherty","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0372","unstructured":"U.S. Food and Drug Administration. BOSULIF [Package Insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0373","unstructured":"U.S. Food and Drug Administration. SPRYCEL [Package Insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0374","unstructured":"U.S. Food and Drug Administration. ICLUSIG [Package Insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0375","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0376","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"10.1016\/j.cardfail.2024.08.045_bib0377","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0378","unstructured":"Janssen Products, LP. YONDELIS\u00ae (trabectedin), Established safety profile. Published 2023.https:\/\/www.yondelis.com\/hcp\/safety.html?&utm_source=google&utm_medium=cpc&utm_campaign=GO-USA-ENG-PS-Yondelis-BC-PH-RN-HCP_Generic&utm_content=Generic+-+Core&utm_term=trabectedin&gclid=CjwKCAjwtqmwBhBVEiwAL-WAYTQDA8YdLzXKXRHdV43gvjaMCb1uYBRc4QD-23xoxA9B2lVfTNud-RoCvfcQAvD_BwE."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0379","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12609-017-0249-4","article-title":"Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer","volume":"9","author":"Nowsheen","year":"2017","journal-title":"Curr Breast Cancer Rep."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0380","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0381","doi-asserted-by":"crossref","unstructured":"Marwick TH, Dewar E, Nolan M, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. Published online September 1, 2024. doi:10.1093\/eurheartj\/ehae574.","DOI":"10.1093\/eurheartj\/ehae574"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0382","doi-asserted-by":"crossref","unstructured":"Barac A, Mauro L, Harnden K. From setbacks to success: building a promising path for strain-guided cardioprotection during anthracycline treatment. Eur Heart J. Published online September 1, 2024. doi:10.1093\/eurheartj\/ehae598.","DOI":"10.1093\/eurheartj\/ehae598"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0383","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale D","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0384","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0385","unstructured":"Gulati G. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial."},{"key":"10.1016\/j.cardfail.2024.08.045_bib0386","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): Extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0387","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0388","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0389","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0390","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0391","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.cardfail.2024.08.045_bib0392","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0393","first-page":"pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0394","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2024.08.045_bib0395","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424003634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916424003634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:56:15Z","timestamp":1739303775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916424003634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":394,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1071916424003634"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}